Comparing Combined Cabergoline and Letrozole to Letrozole Alone for Ovulation Induction in Women with Polycystic Ovary Syndrome Aged 18 to 35

What this Trial Is About

Researchers are studying women with polycystic ovary syndrome PCOS who are seeking to become pregnant. The study compares whether combining two drugs, cabergoline and letrozole, helps increase the rate of ovulation better than using letrozole alone. This randomized controlled trial involves participants diagnosed with PCOS according to the Rotterdam criteria and focuses on ovulation induction to improve fertility outcomes. Participants are randomly assigned to one of two groups. The experimental group takes cabergoline tablets twice on days 2 and 9 of their menstrual cycle plus letrozole tablets daily for five days starting on day 2. The comparison group takes only letrozole tablets daily for five days starting on day 2. Treatments continue for up to three menstrual cycles. Ovarian response is monitored using transvaginal ultrasound to check follicle growth on day 12 of each cycle. Participants will attend multiple visits each cycle for initial assessments, medication administration, ultrasound monitoring, and blood tests to confirm ovulation by measuring progesterone levels. Pregnancy testing and ultrasound for fetal heartbeat are done if menstruation is missed. The main outcome measured is ovulation rate within 21 days after each cycle, with additional monitoring of follicle size, ovulation confirmation, and pregnancy occurrence over 12 weeks.

Cabergoline & Letrozole Versus Letrozole in Ovulation Induction in PCOS